About Transcription initiation protein SPT3 homolog
Transcription initiation protein SPT3 homolog (SUPT3H) is a protein
from Homo sapiens identified by UniProt accession
O75486, 317 residues long.
MolForge cross-references it against 0 known binders and
92 disease associations.
Target properties
| Protein name | Transcription initiation protein SPT3 homolog |
| UniProt accession | O75486 |
| Gene | SUPT3H |
| Organism | Homo sapiens |
| Length | 317 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (92)
Diseases linked to this target (Open Targets).
- cleidocranial dysplasia 1 · score 0.38
- metaphyseal dysplasia-maxillary hypoplasia-brachydacty syndrome · score 0.33
- Metaphyseal dysplasia - maxillary hypoplasia - brachydacty · score 0.33
- body height · score 0.33
- heel bone mineral density · score 0.31
- bone quantitative ultrasound measurement · score 0.31
- appendicular lean mass · score 0.29
- lean body mass · score 0.27
- bone density · score 0.27
- nose morphology measurement · score 0.26
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O75486-F1 | alphafold | PREDICTED | 80.38 | — |
Amino-acid sequence (317 residues)
MNNTAASPMS TATSSSGRST GKSISFATEL QSMMYSLGDA RRPLHETAVL VEDVVHTQLI NLLQQAAEVS QLRGARVITP EDLLFLMRKD KKKLRRLLKY MFIRDYKSKI VKGIDEDDLL EDKLSGSNNA NKRQKIAQDF LNSIDQTGEL LAMFEDDEID EVKQERMERA ERQTRIMDSA QYAEFCESRQ LSFSKKASKF RDWLDCSSME IKPNVVAMEI LAYLAYETVA QLVDLALLVR QDMVTKAGDP FSHAISATFI QYHNSAESTA ACGVEAHSDA IQPCHIREAI RRYSHRIGPL SPFTNAYRRN GMAFLAC
Explore Transcription initiation protein SPT3 homolog with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets